Investigational ADC QLS5132 showed promising clinical benefit and manageable safety in Phase I trial patients with platinum-resistant ovarian cancer.
Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions Representatives: Trevi senior management will be ...
BREATH OF HOPE RI is gearing up for its 3rd Annual 5K on May 2, 2026, in Warwick, bringing the community together to raise ...
AI-based deep learning models can detect interstitial lung disease from lung ultrasound images in patients with systemic ...
ILD was detected in about half of AAV cases, and one-third had fibrotic ILD, indicating a substantial pulmonary fibrosis ...
Most of us probably have a solid, big picture idea of behavior that isn’t good for our bodies. Of course, human health is a ...
Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefit RALEIGH, N.C., April 20, 2026 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
The FDA’s Priority Review designation underscores the potential of enfortumab vedotin plus pembrolizumab to address a critical unmet need in MIBC. By demonstrating improvements in survival and ...
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...
The fatigue and breathlessness program specific to interstitial lung disease is feasible, acceptable, and clinically effective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results